Immunotherapy involves the use of immune checkpoint inhibitors (ICIs) to specifically block immune checkpoints such as PD-L1, CTLA-4, and CD47, thereby disrupting the immunosuppressive tumor microenvironment (25). This evidence concerns the gene CD47 and neoplasm.